ออสเตรเลีย - อังกฤษ - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - droperidol, quantity: 2.5 mg - injection, solution - excipient ingredients: mannitol; tartaric acid; sodium hydroxide; water for injections - anaesthesia droperidol lupin injection is indicated to produce tranquillisation and to reduce the incidence of nausea and vomiting in surgical and diagnostic procedures for premedication, induction, and as an adjunct in the maintenance of general and regional anaesthesia in neuroleptanalgesia in which droperidol lupin injection is given concurrently with a narcotic analgesic, to aid in producing tranquillity and decreasing anxiety and pain.,psychiatry the management of severe agitation, hyperactivity, or aggressiveness in psychotic disorders, including schizophrenic reaction and the manic type of manic depressive illness, or in disturbed states, such as some types of acute brain syndrome and in nonpsychotic acute excitation states.

ออสเตรเลีย - อังกฤษ - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - lidocaine hydrochloride monohydrate, quantity: 53.3 mg (equivalent: lidocaine hydrochloride, qty 50 mg) - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium chloride; sodium hydroxide - for production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

ออสเตรเลีย - อังกฤษ - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - lidocaine hydrochloride monohydrate, quantity: 213.2 mg (equivalent: lidocaine hydrochloride, qty 200 mg) - injection, solution - excipient ingredients: water for injections; sodium chloride; hydrochloric acid; sodium hydroxide - for production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

ออสเตรเลีย - อังกฤษ - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - lidocaine hydrochloride monohydrate, quantity: 42.66 mg (equivalent: lidocaine hydrochloride, qty 40 mg) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; sodium chloride; hydrochloric acid - for production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

ออสเตรเลีย - อังกฤษ - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - lidocaine hydrochloride monohydrate, quantity: 21.32 mg (equivalent: lidocaine hydrochloride, qty 20 mg) - injection, solution - excipient ingredients: sodium hydroxide; sodium chloride; hydrochloric acid; water for injections - for production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

ออสเตรเลีย - อังกฤษ - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - lidocaine hydrochloride monohydrate, quantity: 426.6 mg (equivalent: lidocaine hydrochloride, qty 400 mg) - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; water for injections; sodium hydroxide - for production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

ออสเตรเลีย - อังกฤษ - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - lidocaine hydrochloride monohydrate, quantity: 106.65 mg (equivalent: lidocaine hydrochloride, qty 100 mg) - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - for production of local or regional anaesthesia by nerve block, infiltration injection, caudal or other epidural blocks. treatment or prophylaxis of life-threatening ventricular arrhythmias, including those associated with myocardial infarction, general anaesthesia in patients predisposed to ventricular arrhythmias, digitalis intoxication, or following resuscitation from cardiac arrest.

สหรัฐอเมริกา - อังกฤษ - NLM (National Library of Medicine)

dispensing solutions, inc. - prochlorperazine maleate (unii: i1t8o1jtl6) (prochlorperazine - unii:yhp6ylt61t) - prochlorperazine 10 mg - for control of severe nausea and vomiting. for the treatment of schizophrenia. prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. however, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). when used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see warnings ). the effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4-week clinical studies of outpatients with generalized anxiety disorder. this evidence does not predict that prochlorperazine will be useful in patients with other non-psychot

ออสเตรเลีย - อังกฤษ - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - bupivacaine hydrochloride, quantity: 5 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 5.28 mg/ml) - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; water for injections; sodium hydroxide - indications ,bupivacaine-claris is indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: ,surgical anaesthesia ,epidural block for surgery ,field block (minor and major nerve blocks and infiltration). ,analgesia ,continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. ,field block (minor nerve block and infiltration).

ออสเตรเลีย - อังกฤษ - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - bupivacaine hydrochloride, quantity: 5 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 5.28 mg/ml) - injection, solution - excipient ingredients: hydrochloric acid; sodium chloride; sodium hydroxide; water for injections - indications ,bupivacaine-baxter is indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: ,surgical anaesthesia ,epidural block for surgery ,field block (minor and major nerve blocks and infiltration). ,analgesia ,continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. ,field block (minor nerve block and infiltration).